Key result
In patients undergoing cardiovascular surgery, the use of Surgiflo was associated with similar rates of any documented bleeding event compared to Floseal (6.9% vs 7.2%; P=0.576).
Why the study?
To compare clinical and economic outcomes in patients receiving the current formulation of Surgiflo versus Floseal during cardiovascular surgeries.
Does Surgiflo improve clinical and economic outcomes compared to Floseal in adults undergoing cardiovascular surgery?
Cohort (n=11,536)
Yes
Does Surgiflo improve clinical and economic outcomes compared to Floseal in adults undergoing cardiovascular surgery?
Absolute Event Rate: 6.9% vs 7.2%
p-value: p=0.576
In cardiovascular surgeries, Surgiflo provides similar hemostatic efficacy to Floseal but is associated with lower hospitalization costs and reduced readmission rates.
Surgiflo was associated with similar bleeding rates to Floseal; leaves open whether economic differences justify preference in cardiovascular surgery.
Background: , which had been re-engineered to increase paste viscosity and thus be more adherent to the bleeding surface. Objective: To compare clinical and economic outcomes in patients receiving the current formulation of Surgiflo vs Floseal during cardiovascular surgeries. Methodology: A retrospective analysis was conducted using the Premier Healthcare Database. Eligible patients had an inpatient cardiovascular surgery between 1/1/2013 and 6/1/2018, were ≥18 years old and received the current formulation of Surgiflo or Floseal during surgery. Propensity score matching was performed, with exact matching on the surgery year and surgery type (aortic, coronary artery bypass grafting, valve, or other). Descriptive analysis and generalized estimating equations models compared outcomes between the Surgiflo and Floseal groups. Results: The matched sample included 5768 patients in each group (mean age: 66.5 years; 66.3% male). In the matched sample, rates of any documented bleeding event were similar in Surgiflo and Floseal groups (6.9% vs 7.2%; P = 0.576). Differences in transfusion rates between patients receiving Surgiflo vs Floseal varied by operational definition and timing of measurement but did not differ by >2 percentage points. Compared to Floseal, patients who received Surgiflo experienced longer surgery duration (306.0 vs 299.4 minutes), lower hospitalization cost ($44,146 vs $46,812), and lower odds of readmission at 30, 60, and 90 days post-discharge (all P < 0.05). Inpatient mortality and LOS were comparable between Surgiflo and Floseal (all P > 0.05). Conclusion: In this large study of real-world clinical and economic outcomes after cardiovascular surgery involving the current formulation of Surgiflo vs Floseal, Surgiflo was associated with mostly similar clinical outcomes as compared with Floseal. Differences in selected economic/resource use outcomes were also observed, for which root-cause analysis in future research would be informative.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Cardiovascular surgeries (n=11,536). Surgiflo vs. Floseal was evaluated on Any documented bleeding event (p=0.576). In patients undergoing cardiovascular surgery, the use of Surgiflo was associated with similar rates of any documented bleeding event compared to Floseal (6.9% vs 7.2%; P=0.576).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: